rituximab

View Patient Information

A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	C2B8 monoclonal antibody chimeric anti-CD20 antibody IDEC-C2B8 monoclonal antibody monoclonal antibody IDEC-C2B8 rituximab ABBS rituximab ARRX rituximab biosimilar ABP 798 rituximab biosimilar BI 695500 rituximab biosimilar CT-P10 rituximab biosimilar GB241 rituximab biosimilar IBI301 rituximab biosimilar PF-05280586 rituximab biosimilar RTXM83 rituximab biosimilar SAIT101 rituximab biosimilar SIBP-02 rituximab biosimilar TQB2303 rituximab PVVR rituximab-abbs rituximab-arrx rituximab-pvvr
US brand name:	Riabni Rituxan Ruxience Truxima
Foreign brand name:	Ikgdar Mabtas MabThera
Code name:	ABP 798 BI 695500 CT-P10 IDEC-102 IDEC-C2B8 PF-05280586 rituximab biosimilar JHL1101 RTXM83

rituximab

Search NCI's Drug Dictionary